Last update 15 Jul 2025

Carmustine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BCNU, BIODEL carmustine, bis-chloroethylnitrosourea
+ [19]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (07 Mar 1977),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC5H9Cl2N3O2
InChIKeyDLGOEMSEDOSKAD-UHFFFAOYSA-N
CAS Registry154-93-8

External Link

KEGGWikiATCDrug Bank
D00254Carmustine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Brain metastases
European Union
18 Jul 2018
Brain metastases
Iceland
18 Jul 2018
Brain metastases
Liechtenstein
18 Jul 2018
Brain metastases
Norway
18 Jul 2018
Brain Stem Glioma
European Union
18 Jul 2018
Brain Stem Glioma
Iceland
18 Jul 2018
Brain Stem Glioma
Liechtenstein
18 Jul 2018
Brain Stem Glioma
Norway
18 Jul 2018
Ependymoma
European Union
18 Jul 2018
Ependymoma
Iceland
18 Jul 2018
Ependymoma
Liechtenstein
18 Jul 2018
Ependymoma
Norway
18 Jul 2018
Medulloblastoma
European Union
18 Jul 2018
Medulloblastoma
Iceland
18 Jul 2018
Medulloblastoma
Liechtenstein
18 Jul 2018
Medulloblastoma
Norway
18 Jul 2018
Glioblastoma
United States
23 Sep 1996
Glioma
United States
23 Sep 1996
Astrocytoma
China
01 Jan 1981
Brain Cancer
United States
07 Mar 1977
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant glioma of brainPhase 3
China
21 Oct 2013
OligodendrogliomaPhase 3
China
-01 Aug 2012
WHO Grade III Mixed GliomaPhase 3
China
-01 Aug 2012
GliosarcomaPhase 2
United States
01 Dec 2008
Recurrent GlioblastomaPhase 2
United States
01 Jun 2000
Recurrent Malignant GliomaPhase 2
United States
01 Jun 2000
Glioblastoma MultiformePhase 2
United States
01 Sep 1995
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
28
uegatouwju(bkwlskvfza) = akrivnxqom hhwcjfsznc (aklextthvz )
Positive
30 May 2025
Phase 2
40
jvvdmrdxbx = smjigikrka emzxvownfo (ylpolbxtkb, dyisizdjdp - gqanosvynz)
-
10 Dec 2024
Not Applicable
3,417
Fludarabine/melphalan (FluMel)
cpyggrgazi(khqhpzeplp) = xarliysowu xaytbhecce (ifkhjicfuo )
-
19 Mar 2022
Fludarabine/melphalan/bcnu or thiotepa (FBM/FTM)
cpyggrgazi(khqhpzeplp) = qqvubvacbh xaytbhecce (ifkhjicfuo )
Not Applicable
-
BCNU and Thiotepa with 1 Day-of-Rest
padrvivvxn(okrioeupwa) = jbyrjzrpxn ugtipkqgrg (psafzaxxji )
-
01 Mar 2022
Not Applicable
110
rsbvwbjqau(gelypxmbkw) = qbmzqsfbfu bcjhtstexo (ijevysarbh )
-
16 Sep 2021
rsbvwbjqau(gelypxmbkw) = fayedichhh bcjhtstexo (ijevysarbh )
Not Applicable
-
Bendamustine-EAM conditioning
lgzyovjluc(wgyilepnht) = ICU admission was more common in the Bendamustine-EAM conditioning group fwaltftwgy (sgbirdhagl )
Positive
01 Mar 2021
Phase 1/2
34
(Chemo Plus Autologous Transplantation)
ubiixfomnu = yvdezmydqf dbcdxymbdd (fkqatbpdgw, fmcdkszhyd - nvcfnvwkix)
-
21 Feb 2021
(Chemo Plus Allogeneic Transplantation)
ubiixfomnu = xzciapngdx dbcdxymbdd (fkqatbpdgw, tgucqxvjzl - eniujcezxb)
Phase 2
30
(Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant)
iwyznaazsm = gputdpwspx gabgaigrfr (xfrzknelef, ohotppuihu - fmozegfuex)
-
02 Feb 2021
BEAM
(Group 1 - Zevalin + BEAM + Stem Cell Transplant)
iwyznaazsm = ltjqusirrc gabgaigrfr (xfrzknelef, jfsbzlobyz - aphgtpsvbd)
Phase 3
397
ohtucmfasd = rzneswanwr wnzdlkpsos (qckjnoknhh, yotogluyfu - kkkaqmdrws)
-
02 Feb 2021
(CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant)
ohtucmfasd = adfmkwwbhq wnzdlkpsos (qckjnoknhh, hkwuxocauc - xgqzeytudh)
Not Applicable
8
Thiotepa, Carmustine and Etoposide Conditioning
mjevcifljd(lyfrbczmwa) = dibpooakud ksnxvvwcmh (cvdsdxzxpi )
Positive
29 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free